Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Significant Accounting Policies (Details) - Schedule of Major Customer Data as a Percentage of Total Revenues

v3.24.1
Significant Accounting Policies (Details) - Schedule of Major Customer Data as a Percentage of Total Revenues - Revenue Benchmark [Member] - Customer Concentration Risk [Member]
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Concentration Risk [Line Items]      
Percentage of total revenues 100.00% 100.00% 100.00%
Cipher Pharmaceuticals [Member]      
Concentration Risk [Line Items]      
Percentage of total revenues 11.00% 11.00% 12.00%
Chong Kun Dang Pharmaceuticals Corp [Member]      
Concentration Risk [Line Items]      
Percentage of total revenues 25.00% 25.00% 24.00%
Gebro Holding GmBH [Member]      
Concentration Risk [Line Items]      
Percentage of total revenues 18.00% 18.00% 23.00%
Ewopharma AG [Member]      
Concentration Risk [Line Items]      
Percentage of total revenues 46.00% 46.00% 41.00%